Subscribe To
CLNN / Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates
CLNN News
By GlobeNewsWire
August 30, 2023
Clene to Present at Upcoming September Conferences
SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary more_horizontal
By Zacks Investment Research
May 12, 2023
Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $ more_horizontal
By GlobeNewsWire
March 8, 2023
Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial
Webcast set for 7:30 a.m. ET on March 9 Webcast set for 7:30 a.m. ET on March 9 more_horizontal
By GlobeNewsWire
August 30, 2022
Clene to Present at Upcoming September Investor Conferences
SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary more_horizontal
By The Motley Fool
July 18, 2022
Why Shares of Clene Jumped 11.8% on Monday
The company's lead therapy has shown progress against ALS in preliminary trials. more_horizontal
By Benzinga
July 18, 2022
HC Wainwright Initiates Coverage On This Nanocrystals Stock
H.C. Wainwright initiated coverage on Clene Inc (NASDAQ: CLNN) with a Buy rating and a $16 price target. Clene is focused on the development of more_horizontal
By InvestorPlace
July 14, 2022
Why Is Clene (CLNN) Stock Soaring 23% Today?
Clene (CLNN) stock is heading higher on Thursday following the release of data from a long-term clinical trial of CNM-Au8. The post Why Is Clene (CLNN more_horizontal